• Corpus ID: 35578835

Pharmacokinetics and bioavailability of doxycycline in humans.

  title={Pharmacokinetics and bioavailability of doxycycline in humans.},
  author={G. Campistron and Yvon Coulais and C{\'e}line Caillard and J. Mosser and Henri Pontagnier and Georges Houin},
  volume={36 11},
The bioavailability of a new tablet of 6-deoxy-5-hydroxytetracycline (doxycycline, Doxycline Plantier) was estimated relatively to an oral solution and a commercially available capsule. Each form was administered to 12 healthy volunteers according to a replicated latin square. Statistical analysis of non-compartmental pharmacokinetic parameters - maximum concentrations, corresponding time, area under the plasma concentrations curve and unchanged amounts recovered in the urine - failed to show… 
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.
Though incompletely understood, the pharmacodynamic properties of the tetracyclines and glycylcyclines are summarized.
Clinical Pharmacokinetics of Doxycycline and Minocycline
The influence of age, renal disease, malnutrition and hyperlipidaemia is reviewed, together with the main pharmacokinetic interactions of doxycycline and minocycline.
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
A population pharmacokinetic model was developed with data from healthy subjects and infected patients and used to establish interpretive criteria for in vitro susceptibility testing and dosing regimens of omadacycline for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate.
It is concluded that a biowaiver is appropriate for IR solid oral dosage forms containing doxycycline hyclate as the single Active Pharmaceutical Ingredient (API) provided that the test product contains only excipients present in doxy Cyclate IR solid Oral drug products approved in the International Conference on Harmonization or associated countries.
Factors Involved in the Pharmacokinetics of COL‐3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies
Preliminary assessment of COL‐3 in 35 patients with refractory metastatic carcinoma demonstrated apparent nonlinear pharmacokinetics with highly variable oral clearance, possibly due to dissolution rate‐limited absorption.
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
  • M. Rudek, W. Figg, E. Reed
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy and was well tolerated without the use of sunblock, and the dose of 36 mg/m2/d is recommended for phase II trials.
Phase I C linical T rial o f O ral C OL-3, a M atrix Metalloproteinas e I nhibitor, i n P atients W ith R efractory Metastatic C ancer
COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy and was well tolerated without the use of sunblock, and the dose of 36 mg/m 2 /d is recommended for phase II trials.
Inhibition of Trypsin-Like Cysteine Proteinases (Gingipains) fromPorphyromonas gingivalis by Tetracycline and Its Analogues
Results indicate a new activity of tetracyclines as cysteine proteinase inhibitors and may explain the therapeutic efficiency of these antibiotics in the treatment of periodontitis.